Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856791 · ClinicalTrials.gov registry record · Phase 2
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
A Phase 2 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00856791 is a Phase 2 study that has completed, run by Traws Pharma. The registered enrollment target is 1 participants.
The verdict
NCT00856791, a Phase 2 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
ON 01910.Na has undergone preclinical and clinical phase I studies showing activity in patients with progressing ovarian cancer resistant to platinum-based chemotherapies. This study will look at a larger population of patients to determine whether treatment with ON 01910.Na has an effect on progression free survival rates in patients with platinum-resistant ovarian cancer. ON 01910.Na will be given as an intravenous infusion over 2 hours on days 1, 4, 8, 11, 15, and 18 of a 28-day cycle. Patients will be treated for 6 or more cycles.
Interventions
- DRUG ON 01910.Na
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856791
The ClinicalTrials.gov registry entry for NCT00856791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ON 01910.Na is the first listed.
NCT00856791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856791 about?
NCT00856791 is a clinical study titled "Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients". ON 01910.Na has undergone preclinical and clinical phase I studies showing activity in patients with progressing ovarian cancer resistant to platinum-based chemotherapies. This study will look at a larger population of patients to determine whether treatment with ON 01910.Na has an effect on progres...
What is the current status of trial NCT00856791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00856791?
The interventions under investigation include: ON 01910.Na (DRUG).
Who is sponsoring clinical trial NCT00856791?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.